ArticlePublic health weekly report2026
Analysis of Clinical Characteristics and Treatment Efficacy in the Korean Hepatitis B Cohort.
Article in Public health weekly report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The Korea hepatitis B cohort study is a prospective cohort established to analyze the epidemiological characteristics and treatment outcomes of individuals with chronic hepatitis B virus (HBV) infection in the Republic of Korea (ROK). This study aims to provide evidence to support HBV control, prevention strategies, and national policy development. Methods: Adults aged ≥19 years with chronic hepatitis B were enrolled at five regional medical institutions across ROK. Additional blood samples were collected from participants who consented to biospecimens donation. This prospective observational study did not interfere with routine clinical care. Data on antiviral treatment, treatment continuation, and liver-related outcomes, including hepatocellular carcinoma, were collected. Results: Between 2015 and 2024, a total of 3,221 participants were enrolled in the study. After excluding 422 individuals who were lost to follow-up, clinical data from 2,799 participants were collected. On average, 4.2 longitudinal blood samples per participant were obtained at 6- to 12-month intervals. The cohort exhibited epidemiological patterns consistent with previously reported trends in the ROK. The use of effective antiviral therapy was associated with better management of chronic hepatitis B. Conclusions: The continuation of this study will enable systematic and efficient monitoring of the current status and long-term clinical outcomes of patients with chronic hepatitis B. These findings are expected to inform revisions of national clinical practice guidelines and support the development of public health policies in the ROK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.